RCS - Immupharma PLC - IMMUPHARMA ATTENDING BIO-EUROPE

ImmuPharmaAnnouncement

27/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nRSa8330Ea&default-theme=true

RNS Number : 8330E  Immupharma PLC  27 October 2025

RNS REACH : 27 NOVEMBER 2025

ImmuPharma PLC

("ImmuPharma" or the "Company")

IMMUPHARMA ATTENDING BIO-EUROPE

3-5 November 2025, Vienna

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr
Sebastien Goudreau, CSO will be attending the forthcoming Bio-Europe
Conference in Vienna, from 3-5 November 2025.

BIO-Europe Vienna 2025, is the 31st annual premier biopharma partnering event.
It brings together over 5,700 life science professionals from more than 3,000
companies across 60+ countries, facilitating more than 30,000 one-to-one
meetings. This event makes it the leading life science partnering forum in
Europe, fostering innovation, collaboration and growth in the biotech sector.

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550 (about%3Ablank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)

 Patrick Claridge, Bob Pountney                                        +44 (0) 20 3650 3650

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk) .

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABRBDGCXDDGUS



            Copyright 2019 Regulatory News Service, all rights reserved